Why 340B Compliance Feels Harder Than It Should. And What’s Actually Driving It

21 Jul Why 340B Compliance Feels Harder Than It Should. And What’s Actually Driving It

Managing a 340B program isn’t difficult because the rules are ambiguous. It’s difficult because the rules are clear, the stakes are significant, and the organizational infrastructure most covered entities have built around the program was never designed to carry that weight. The compliance burden lives in the gap between knowing what’s required and being able to prove it under audit conditions.

Key Takeaways

• The most common source of audit findings isn’t a policy violation. It’s documentation that can’t withstand scrutiny because accountability was never clearly assigned.
• HRSA’s audit process tests whether compliance is operationally implemented, not just whether a policy document exists.
• Contract pharmacy relationships, patient eligibility documentation, and duplicate discount prevention are consistently the highest-risk areas in HRSA audits.
• Waiting until an audit notice arrives to assess your compliance posture is almost always the most expensive timing decision a covered entity makes.
• Credible 340B consulting produces systems and documented processes, not just reports. And the difference between those two outcomes shows up directly in audit results.

Why Does 340B Compliance Feel Like a Moving Target Even When the Rules Haven’t Changed?

The regulations governing the 340B program haven’t shifted as dramatically as the compliance burden implies. What has changed is the depth and frequency of enforcement.

HRSA’s Office of Pharmacy Affairs has steadily increased audit activity over the past several years, and the documentation expectations accompanying those audits are more exacting than they once were. A compliance posture that was technically sound and practically unexamined five years ago may now produce findings. Not because the underlying rules changed, but because HRSA auditors now examine how covered entities demonstrate compliance, not simply whether they claim it.

The gap between being compliant and being able to prove compliance is where most organizations get hurt. You’re not just managing a program. You’re managing a documentation architecture that has to hold up under adversarial review. Those are different jobs, and most covered entities are staffed and resourced for the first one.

What’s the Real Root Cause Behind Recurring Audit Findings?

It’s almost never negligence. It’s diffusion of accountability across roles that were never designed to own 340B compliance in full.

In a typical community health center or hospital, the 340B program touches the pharmacy director, the compliance officer, the billing department, the CFO, and sometimes the IT team. Each of those roles holds a piece of the program. None holds the whole thing. When HRSA requests documentation that spans all of those functions. Patient eligibility records, dispense data, duplicate discount prevention evidence. The gaps between departments become visible in ways they weren’t before.

Consider a common scenario: a covered entity has maintained a contract pharmacy relationship for several years without incident. The pharmacy is properly registered. The split-billing software is running. But when an audit arrives, the covered entity can’t produce a current, signed contract pharmacy agreement reflecting updated HRSA guidance on accumulator programs. The pharmacy arrangement is compliant. The documentation isn’t. That’s not a pharmacy problem. It’s an accountability structure problem.

It’s one of the most consistent patterns seen across HRSA 340B audits, and it’s among the most preventable.

Is the 340B Program Too Complex for Internal Management?

That’s not quite the right question. The program isn’t too complex for internal management. It’s too complex for internal management without a documented compliance framework that assigns ownership, tracks metrics, and creates audit-ready records as a matter of routine rather than crisis response.

A useful way to think about this is what practitioners sometimes call a Compliance Accountability Matrix: a structured mapping of the four core 340B program functions. Eligibility verification, dispense tracking, contract pharmacy oversight, and duplicate discount prevention. Against three accountability dimensions: who owns it, how it’s documented, and how frequently it’s reviewed. When any cell in that matrix is unassigned or undocumented, that’s a finding waiting to happen.

Most organizations that struggle with 340B program management aren’t struggling because they lack knowledgeable people. They’re struggling because no one has built that matrix explicitly, assigned clear ownership, and established a review cadence that produces audit-ready records continuously rather than reactively. Reviewing what covered entities must prepare for in an HRSA audit makes clear that the preparation requirements are far more operational than most compliance officers anticipate going in.

Why Does Hiring a 340B Consultant Sometimes Feel Like It Made Things More Complicated?

Because not all 340B consulting delivers the same kind of help.

There’s a meaningful difference between a consultant who explains what the regulations require and one who helps you build the operational infrastructure to satisfy them. The first type produces a report. The second produces a system. Most covered entities who’ve walked away from a frustrating consulting engagement received the report.

The most confident pitch is often the least trustworthy signal. Advice that sounds authoritative in a presentation can quietly unravel under HRSA audit conditions. Credible 340B consulting is defined by documented processes, measurable compliance metrics, and a demonstrable track record with actual audit outcomes. Not by the clarity of the slides.

When you’re evaluating a consulting partner, the relevant question isn’t “do they know the rules?” It’s “have they sat across from HRSA auditors and helped covered entities come out the other side?” That distinction shapes everything about how they’ll approach your program.

Ponaman Healthcare Consulting’s team includes consultants, auditors, analysts, and medical and legal specialists whose work is built around that kind of practical audit experience. The firm’s 340B compliance monitoring and audit support services are designed specifically around what HRSA actually examines, not just what the statute says.

Which Program Areas Generate the Most Findings. And Why?

Consistently, three areas produce the highest concentration of audit findings: contract pharmacy compliance, patient eligibility documentation, and duplicate discount prevention.

Contract pharmacy relationships are carrying significant risk right now. The regulatory environment has shifted materially, and what covered entities need to know about contract pharmacy compliance has become one of the most actively scrutinized areas in recent HRSA audits. Covered entities that haven’t reviewed their contract pharmacy agreements and data-sharing arrangements against current guidance are carrying more exposure than their records reflect.

Patient eligibility is the other consistent pressure point. The documentation standard isn’t just that a patient was eligible at the time of a dispense. It’s that the covered entity can demonstrate, at the claim level, that eligibility was verified at the time of the encounter. Retroactive documentation doesn’t satisfy this requirement. The verification process has to be built into the workflow, not reconstructed after the fact.

Duplicate discount prevention generates the most operational confusion. The requirement isn’t simply that duplicate discounts didn’t occur. HRSA wants to see that the covered entity has a functioning control system that would have caught them if they had. The auditor is looking for the mechanism, not just the outcome.

Comparing Your Options: Acting Now vs. Waiting

The consulting fee isn’t the expensive option. The expensive option is discovering compliance gaps after HRSA is already in the room.

Who Gets the Most From 340B Consulting. And When Does It Matter Most?

340B consulting matters most when the stakes are highest: when an audit notice has arrived, when a program is being implemented for the first time, when contract pharmacy relationships are being restructured, or when an organization has grown and the compliance infrastructure hasn’t kept pace with that growth.

It matters less for covered entities with a fully dedicated 340B compliance team, current documentation across all program functions, and recent direct audit experience. Those organizations exist. They’re not common.

For most covered entities. Community health centers managing multiple service delivery sites, hospitals with complex split-billing arrangements, FQHCs navigating the ongoing regulatory scrutiny of the 340B program. The question isn’t whether support is warranted. It’s whether that support comes before or after a finding.

One genuine limitation worth naming: there’s no compliance engagement that produces overnight results. A covered entity with significant documentation gaps and complex contract pharmacy arrangements should plan for several months of structured work before reaching a defensible posture. Not several weeks. The timeline depends heavily on the current state of documentation and how many program functions need systematic restructuring. What doesn’t change is the direction: every month of consistent, documented compliance practice makes the program more defensible, not less.

Frequently Asked Questions

How do I know whether my 340B program has compliance gaps before an audit surfaces them?

The most reliable indicator is a documentation review that tests whether you can produce audit-ready evidence for each compliance requirement. Not just confirm that a policy exists. If your team would need more than 48 hours to pull together patient eligibility records, dispense data, and contract pharmacy agreements for a given period, that’s a gap. A pre-audit compliance review is specifically designed to find those gaps before HRSA does.

What does HRSA actually look for during a 340B audit?

HRSA auditors examine four core areas: patient eligibility verification, prevention of diversion to ineligible patients, prevention of duplicate discounts, and contract pharmacy compliance. They’re not reviewing whether policies exist. They’re testing whether those policies are operationally implemented and whether the documentation supports the claims being made. It’s an evidentiary process, not a policy check.

Is it too late to get outside help if I’ve already received an audit notice?

No. But the options narrow. With an audit notice in hand, the priority shifts from gap remediation to audit response strategy: organizing documentation, anticipating information requests, and positioning the covered entity’s compliance posture as clearly as the record supports. Ponaman Healthcare Consulting has supported covered entities at every stage of the audit process, including active audits and appeals. Earlier engagement gives more options. It doesn’t mean late engagement is without value.

What’s the difference between a compliance review and an independent external audit?

A compliance review is an internal-facing assessment that identifies gaps and recommends remediation. A tool for the covered entity to improve its program before external scrutiny arrives. An independent external audit is a formal, documented evaluation that produces findings an organization can use to demonstrate compliance to HRSA or other stakeholders. Both serve distinct purposes, and covered entities facing regulatory scrutiny often need both at different points.

How long does it realistically take to bring a 340B program to a defensible compliance posture?

It depends on the current state of documentation and the complexity of the program. A covered entity with focused documentation gaps and a single pharmacy can often reach a defensible posture through several months of structured work. Organizations with multiple contract pharmacies, complex eligibility populations, or prior findings will require more time. There’s no fixed universal timeline. But the work compounds. Consistent, documented compliance practice over time is both more defensible and more sustainable than pre-audit scrambling.

Can a 340B consultant help after findings have already been issued from a prior audit?

Yes. And this is one of the highest-value moments for outside support. Prior findings create a corrective action obligation, and how that obligation is documented and fulfilled directly affects the outcome of any future audit. For findings that remain in place, the goal is building corrective action documentation that protects the program going forward. How that record is constructed matters significantly.

What should I actually ask a 340B consulting firm before engaging them? Ask how many HRSA audits they’ve directly supported and what their experience with audit appeals looks like. Ask whether they can walk you through the compliance framework they’d apply to your specific program. Not just describe it in general terms, but show you the structure. The answers tell you whether you’re hiring someone who understands the regulations or someone who’s been present when those regulations were tested under real audit conditions.

If you’ve been meaning to assess your program’s compliance posture and haven’t gotten there yet, or if an audit notice has already arrived, that’s the moment to act. Contact Ponaman Healthcare Consulting for a compliance review that tells you exactly where your program stands, what’s at risk, and what it takes to address it before HRSA finds it first.